N/A N=102 Metformin in Overweight Type 2 Diabetes Mellitus
Obesity · Type 2 Diabetes Mellitus
Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=88 Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes
Type 2 Diabetes Mellitus · Obesity
Primary: Fasting Plasma Glucose <126 mg/dL and HbA1c < 6.5% at Three Years of Follow-up. — 13; 5; 42; 0 % of patients — p=0.60
N/A N=28 Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises
Diabetes Mellitus, Type 2
Primary: First-Phase Insulin Release (FPIR) — 264; 339; 197; 359 microunits/ml
N/A N=35 Resolution of Type 2 Diabetes Mellitus: Intensive vs. Conventional Glycaemic Control After Obesity Surgery
Type 2 Diabetes Mellitus · Obesity
Primary: Percentage of Patients With Type 2 Diabetes Mellitus Who Achieve Fasting Blood Glucose of Less Than 5.6 mmol/l and/or HbA1c of Less Than 6% — 4; 4 Participants
Phase 2 N=120 A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes
Diabetes Mellitus Type 2
Primary: Percent Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 12 — 0.0005; 0.0029; 0.0007; 0.0004 Percent Change
N/A N=57 Insulin-sensitive Obesity: Lessons From Longitudinal Data
Insulin Sensitivity/Resistance · Obesity
Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year
N/A N=14 The Effect of Hypoxia on Type 2 Diabetes and Weight Loss
Type2 Diabetes
Primary: Δ Mean AUC (Area Under the Curve) Plasma [Glucose] — -17.7; 54.9 mmol.min.L-1
Phase 3 N=66 Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women
Diabetes Prevention in Women After GDM Who Are at High-risk
Primary: Change in Body Weight — -21.5; -12.5; -4.4 kilograms — p=<0.032
N/A N=80 Effects of Obesity Treatments on Food Preferences and Metabolism
Obesity · Type 2 Diabetes Mellitus
Primary: Change in Energy Intake From Baseline — 500; 310; 482; 5 kcal
N/A N=78 Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM
Diabetes Mellitus, Type II
Primary: Percent Change in Plasma Triglycerides — -2.0; 16.0; -5.0; -5.0 percent change
Phase 3 N=699 Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)
Diabetes Mellitus, Type II
Primary: Treatment Failure (Loss of Glycemic Control) — 120; 90; 109; 112 participants
Phase 2 N=23 Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus
Type 2 Diabetes Mellitus · Obese · Overweight
Primary: Change in Postprandial Glucose — -2803; 629 mmol/6hr — p=<0.05
Phase 4 N=21 U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod
Type 2 Diabetes · Insulin Resistance
Primary: Improvement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c) — -1.23 HbA1c percentage
N/A N=60 Comparison Effects Of Different Exercise Approaches On Type 2 DM Women
Type 2 Diabetes
Primary: Glycosylated Hemoglobin Change — 6.82; 7.17; 6.80; 6.33 percentage of glycosylated hemoglobin — p=0.830
Phase 3 N=46 YH1 in Poorly Controlled Type 2 Diabetes
Type 2 Diabetes
Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks — -11.1; 0.0 percentage change
Phase 4 N=130 Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.
Type 2 Diabetes Mellitus (T2DM)
Primary: Number of Patients With Clinically Significant Weight Reduction (>5%) Compared to Baseline at Month 12 — 50; 4; 50; 26 Participants
N/A N=88 Beta Cell Restoration Through Fat Mitigation
Prediabetes · Type 2 Diabetes · Obesity
Primary: Steady State Beta Cell Compensation — 3.01; 3.19 (nmol/L) adjusted for M/I — p=0.05
Phase 2 N=49 Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Change From Baseline to Day 28 in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4hrs) as Measured by Mixed-meal Tolerance Test…
Phase 2 N=24 Exeantide in Type 2 Diabetes on Insulin
Type 2 Diabetes
Primary: Fasting Insulin — 12.7; 13.1; 16.4; 13.9 μU/mL
Phase 4 N=371 Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients
Type 2 Diabetes Mellitus
Primary: Mean Change From Baseline at Week 16 (95% Confidence Interval) in Glycosated Hemoglobin A1c (HbA1c) (Last Observation Carried Forward) - Full Analysis Set (FAS) — -1.95…
Phase 4 N=130 Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes · Coronary Heart Disease
Primary: Change in E to A Ratio — 1.04; 1.25 Ratio — p=<0.01
N/A N=1,369 Computer Automation for Diagnosis and Management of Childhood Type 2 Diabetes
Type 2 Diabetes
Primary: Number of Children With Documented Risk Factors for Type 2 Diabetes — 283; 282 Participants
Phase 2 N=49 A Study to Evaluate the Effect of ORMD-0801 in Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Area Under the Curve (AUC(0-16)) of Endogenous Glucose Production — 3436.8; 3139.3 mg*hr/dL — p=0.1628
N/A N=58 Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL
Phase 4 N=60 Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment
Diabetes · Diabetes Mellitus, Type 2
Primary: Percentage Change in Trunk Fat Mass (Defined as Peripheral Fat Ratio) — 0.366; 1.011 percent change — p=0.849
Phase 2 N=196 A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus
Obesity and Diabetes Mellitus, Type 2
Primary: Percent Change From Baseline in Body Weight at Week 12 — -0.70; -5.25; -6.55; -7.92 Percent Change — p=<.001
Phase 2 N=20 A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) Through the End of the Up-titration Period…
N/A N=10 EndoBarrier in Obese Subjects With Type 2 Diabetes Mellitus
Type 2 Diabetes · Obesity
Primary: Changes in Insulin Sensitivity — 0.97 milligram per kilogram per minute — p=0.001
Phase 3 N=604 BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
Obesity
Primary: Co-primary Endpoint- Percentage of Participants Achieving Greater Than or Equal to 5% Weight Loss From Baseline to Week 52 — 37.5; 44.7; 16.1 percentage of participants…
N/A N=36 Exercise in Obese Diabetic Patients With Chronic Kidney Disease
Chronic Kidney Disease
Primary: Change in Proteinuria — -34; -133 mg/g creatinine — p=0.04